| HIGHLIGHTS FROM ICAAC
�97 The CHEESE Study
(M61003) FORTOVASE� vs. indinavir
Dr. J. Borleffs of University Hospital, Utrecht, presented
data from the first head-to-head comparative study of two protease inhibitor-containing
triple combination regimens. This randomized, open-label, parallel-group, multicenter
pilot study compared FORTOVASE + AZT + 3TC versus indinavir + AZT + 3TC. Subjects were
HIV-infected, either antiretroviral-na�ve or < 12 months� AZT experience, CD4
< 500 and/or HIV RNA of > 10,000 and/or HIV-related signs or symptoms.
The results at week 12 showed that both the FORTOVASE and
indinavir regimens were equally effective in suppressing viral load, demonstrating mean
decreases from 5.17 log10 and 5.70 log10 to 2.6 log10,
respectively. All study participants achieved HIV RNA levels below the limit of detection
using the Roche Amplicor� commercial assay.
The mean CD4 count rose 40 percent in the subjects taking
FORTOVASE, versus an increase of only 2 percent in those subjects taking indinavir. No
adverse effects related to FORTOVASE were reported.
Table of Contents
|
